Stents

Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to have a heart attack than those whose treatment fol...

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is more cost effective and offers a higher quality of life than a best-in-class, permanent,...

September 26, 2014 — In response to new science showing that complete revascularization of all significantly blocked arteries leads to better outcomes in some heart attack patients, the American College of Cardiology (ACC) has withdrawn its Choosi...

Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leading metallic XIENCE...

Stents, Self-Apposing Stent, Stentys
Stentys announced that the Self-Apposing Stent has been implanted more than 10,000 times in patients worldwide
InspireMD, MGuard, CGuard, drug-eluting stent, MASTER II, CARENET, trials
InspireMD, Inc. announced results from two important clinical trials. Thirty-day results from the MASTER II trial, which enrolled 310 of a planned 1,114...
bioresorbable stents
Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely expected to overtake metallic stents in the...
stents, bioresorbable, clinical trial, clinical study
Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. 
The Abbott family of Xience everolimus-eluting coronary stents—including the Xience V, Xience nano, Xience Prime, Xience Xpedition, and
MicroVention Inc.’s Low-Profile Visualized Intraluminal Support Device (LVIS and LVIS Jr.) is a stent and delivery system used to...
Boston Scientific received U.S. Food and Drug Administration (FDA) approval for the Rebel platinum chromium coronary stent system, the...

Articles

bioresorbable stents
Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely expected to overtake metallic stents in the...
DAPT study
Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop...
VIVA, VIVA Physicians, Peripheral, Carotid Artery Device, clinical trial results
Viva Physicians, a not-for-profit organization in the field of vascular medicine and intervention, announce clinical trial results and other new happenings at...
October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is...

Video Center

The America College of Cardiology has released its list of key late-breaking clinical trials at the...
4 days 5 hours ago
As editor of DAIC, I keep a close watch on trends in cardiovascular technology and try to predict...
3 weeks 4 days ago
There were a few intriguing technology trends at the Radiological Society of North America (RSNA)...
5 weeks 2 days ago
The webinar "State of the Art in MRI Pediatric Brain Perfusion Imaging" educates participants about the state of the art clinical and emerging translational...
This webinar discusses why contemporary adult cardiac interventions require significant ionizing radiation with potential health risks to both the patient and...
This webinar explained the benefits of better access, productivity and revenue cycle efficiency in a modern cardiovascular information system (CVIS...